Levobunolol

From Self-sufficiency
Jump to: navigation, search
Levobunolol
File:Levobunolol structural formulae.png
Systematic (IUPAC) name
(S)-5-{[3-(tert-butylamino)-2-hydroxypropyl]oxy}-3,4-dihydronaphthalen-1(2H)-one
Clinical data
Pregnancy
category
  • C
Routes of
administration
Topical (eye drops)
Legal status
Legal status
Pharmacokinetic data
Biological half-life 20 hours
Identifiers
CAS Number 47141-42-4
ATC code S01ED03 (WHO)
PubChem CID 39468
DrugBank APRD00165
Chemical data
Formula C17H25NO3
Molar mass 291.385 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Levobunolol (AK-Beta, Liquifilm, Betegan) is a non-selective beta blocker. It is used topically to manage glaucoma.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

  • Ishibashi T, Yokoi N, Kinoshita S (2003). "Comparison of the effects of topical levobunolol and timolol solution on the human ocular surface". Cornea. 22 (8): 709–15. doi:10.1097/00003226-200311000-00001. PMID 14576520. 
  • Ogasawara H, Yoshida A, Fujio N, Konno S, Ishiko S (1999). "[Effect of topical levobunolol on retinal, optic nerve head, and choroidal circulation in normal volunteers]". Nippon Ganka Gakkai Zasshi. 103 (7): 544–50. PMID 10443129. 
  • Leung M, Grunwald J (1997). "Short-term effects of topical levobunolol on the human retinal circulation". Eye. 11 ( Pt 3): 371–6. PMID 9373479. 
de:Levobunolol

es:Levobunolol